Add to ORKGPurpose: To investigate the efficacy of concurrent hy-pe ctionated radiation therapy (HFX RT) and low-dose daily chemotherapy (CHT) in stage III non-small-cell lung cancer (NSCLC). Patients and Methods: Between January 1990 and December 1991, 131 patients with histologically or cyto-logically confirmed stage III NSCLC, Karnofsky perfor-mance status (KPS) _ 50, and no previous therapy were randomly treated as follows: group I, HFX RT with 1.2 Gy twice daily to a total dose of 69.6 Gy (n = 66); and group II, same HFX RT with CHT consisting of 50 mg of carboplatin (CBDCA) and 50 mg of etoposide (VP-16) given on each RT day (n = 65). Results: Group II patients had a significantly longer suiv- time than group I patients, with a median sur
Concomitant administration of chemotherapy and radiotherapy is currently recognized as the standard ...
IntroductionThe optimal treatment for patients with stage IIIA to IIIB non-small cell lung cancer (N...
Background:To determine the feasibility of combining concurrent carboplatin/paclitaxel and thoracic ...
Purpose: The purpose of this study was to determine survival, local and distant control, toxicity, a...
Purpose: A randomized prospective study was conducted to compare the efficacy of early or late alter...
PURPOSE: The primary objective of this study was to compare the survival of patients with unresectab...
This study was conducted to evaluate clinical outcomes following definitive concurrent chemoradiothe...
PURPOSE: A Non-uniform Fractionation schedule of large priming doses combined with concurrent chemot...
The purpose of this study was to determine in limited small-cell lung cancer if locoregional irradia...
We aimed to evaluate the feasibility and efficacy of hypofractionated involved-field radiation thera...
To compare once-daily radiation therapy (qdRT) with hyperfractionated accelerated radiation therapy ...
Purpose: We conducted a randomized trial to com-pare gemcitabine-cisplatin with etoposide-cisplatin ...
Background: Although concurrent chemoradiation (CCRT) is the standard of care for stage III non-smal...
Purpose: Recent studies have suggested the superior-ity of concurrent chemoradiotherapy and the effi...
PURPOSE: Standard therapy for unresectable stage III non-small-cell lung cancer includes concomitant...
Concomitant administration of chemotherapy and radiotherapy is currently recognized as the standard ...
IntroductionThe optimal treatment for patients with stage IIIA to IIIB non-small cell lung cancer (N...
Background:To determine the feasibility of combining concurrent carboplatin/paclitaxel and thoracic ...
Purpose: The purpose of this study was to determine survival, local and distant control, toxicity, a...
Purpose: A randomized prospective study was conducted to compare the efficacy of early or late alter...
PURPOSE: The primary objective of this study was to compare the survival of patients with unresectab...
This study was conducted to evaluate clinical outcomes following definitive concurrent chemoradiothe...
PURPOSE: A Non-uniform Fractionation schedule of large priming doses combined with concurrent chemot...
The purpose of this study was to determine in limited small-cell lung cancer if locoregional irradia...
We aimed to evaluate the feasibility and efficacy of hypofractionated involved-field radiation thera...
To compare once-daily radiation therapy (qdRT) with hyperfractionated accelerated radiation therapy ...
Purpose: We conducted a randomized trial to com-pare gemcitabine-cisplatin with etoposide-cisplatin ...
Background: Although concurrent chemoradiation (CCRT) is the standard of care for stage III non-smal...
Purpose: Recent studies have suggested the superior-ity of concurrent chemoradiotherapy and the effi...
PURPOSE: Standard therapy for unresectable stage III non-small-cell lung cancer includes concomitant...
Concomitant administration of chemotherapy and radiotherapy is currently recognized as the standard ...
IntroductionThe optimal treatment for patients with stage IIIA to IIIB non-small cell lung cancer (N...
Background:To determine the feasibility of combining concurrent carboplatin/paclitaxel and thoracic ...